In 2024, an experimental animal study by Jiang et al. explored the mechanisms by which leflunomide may attenuate atherosclerosis and improve cardiovascular outcomes by regulating lipid metabolism and endothelial dysfunction via the dihydroorotate dehydrogenase (DHODH)/AMPK signaling pathway [23]. Here, DHODH is linked to endothelial dysfunction.